Whole Blood Gene Expression Profile Associated with Spontaneous Preterm Birth in Women with Threatened Preterm Labor

Yujing Jan Heng1*, Craig Edward Pennell2, Hon Nian Chua3, Jonathan Edward Perkins1, Stephen James Lye1

1 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 2 School of Women’s and Infants’ Health, University of Western Australia, Crawley, WA, Australia, 3 Institute for Infocomm Research, Agency for Science, Technology and Research, Singapore, Singapore

Abstract

Threatened preterm labor (TPTL) is defined as persistent premature uterine contractions between 20 and 37 weeks of gestation and is the most common condition that requires hospitalization during pregnancy. Most of these TPTL women continue their pregnancies to term while only an estimated 5% will deliver a premature baby within ten days. The aim of this work was to study differential whole blood gene expression associated with spontaneous preterm birth (sPTB) within 48 hours of hospital admission. Peripheral blood was collected at point of hospital admission from 154 women with TPTL before any medical treatment. Microarrays were utilized to investigate differential whole blood gene expression between TPTL women who did (n = 48) or did not have a sPTB (n = 106) within 48 hours of admission. Total leukocyte and neutrophil counts were significantly higher (35% and 41% respectively) in women who had sPTB than women who did not deliver within 48 hours (p < 0.001). Fetal fibronectin (fFN) test was performed on 62 women. There was no difference in the urine, vaginal and placental microbiology and histopathology reports between the two groups of women. There were 469 significant differentially expressed genes (FDR < 0.05); 28 differentially expressed genes were chosen for microarray validation using qRT-PCR and 20 out of 28 genes were successfully validated (p < 0.05). An optimal random forest classifier model to predict sPTB was achieved using the top nine differentially expressed genes coupled with peripheral clinical blood data (sensitivity 70.8%, specificity 75.5%). These differentially expressed genes may further elucidate the underlying mechanisms of sPTB and pave the way for future systems biology studies to predict sPTB.

Citation: Heng YJ, Pennell CE, Chua HN, Perkins JE, Lye SJ (2014) Whole Blood Gene Expression Profile Associated with Spontaneous Preterm Birth in Women with Threatened Preterm Labor. PLoS ONE 9(5): e96901. doi:10.1371/journal.pone.0096901

Editor: Kang Sun, Fudan University, China

Received September 12, 2013; Accepted April 13, 2014; Published May 14, 2014

Copyright: © 2014 Heng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Dr Heng is a Canadian Institutes of Health Research fellowship recipient. This study was funded by March of Dimes (#21-Fy04-171 and #21-Fy10-204). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: heng@lunenfeld.ca

Introduction

Preterm birth (PTB; birth at <37 weeks of gestation) occurs in about 8–11% of pregnancies worldwide and remains the main cause of perinatal mortality and morbidity in the developed world [1]. Medical advances have increased the survival rates of premature babies; however, premature infants remain vulnerable to disabilities such as respiratory disorders, cognitive impairment, blindness, deafness etc. [2]. In later life, they may face complications such as motor and sensory impairment, learning difficulties and behavioral issues. Prematurity leads to an immediate and long term emotional and financial burden to families, communities and the health care system [3–7].

Threatened preterm labor (TPTL) is defined as persistent premature uterine contractions between 20 and 37 weeks of gestation and may include other symptoms such as pelvic pressure, backache, increased vaginal discharge, menstrual-like cramps, bleeding/show and shortened cervix [8–11]. Treatment of TPTL involves administration of tocolytic agents to temporarily inhibit uterine contractions and prolong the pregnancy up to 48 hours. This 48 hour window serves to achieve both the benefits of corticosteroid administration on fetal lung maturation as well as the ability to transport the woman to a tertiary hospital with advanced neonatal facilities [12,13].

Generally, labor contractions in the majority of TPTL women will cease and they often continue their pregnancies to term [14]; while approximately 5% of these women will progress into true PTL and deliver a premature baby within 10 days [15]. Thus, women in “false labor” are subjected to unnecessary hospitalization, medical intervention, psychologic stress, exposed to drug side effects and contribute to healthcare costs [16,17]. For example, although corticosteroids augment fetal lung maturity and reduce respiratory distress syndrome, intraventricular hemorrhage and neonatal mortality in premature infants [10], their longer term side effects remain unclear [19–22].

There is limited success for clinicians to accurately stratify TPTL women into “true PTL” or “false labor” at the point of hospital admission. Currently, predicting PTB involves the assessment of clinical risk factors [23], detecting a short cervix (<15 mm) [1,24] and the presence of fetal fibronectin (fFN) in the cervicovaginal fluid [9,25]. fFN testing is clinically useful for its high negative predictive value (NPV) [15]. However, fFN cannot
be performed on women who had prior vaginal/cervical examination, unprotected sexual intercourse, antepartum hemorrhage or ruptured fetal membranes as these factors can influence the fFN test results [26]. As a result, about 50% of TPTL women are generally ineligible for fFN testing.

The ability to predict PTB at point of hospital admission would provide clinicians the opportunity to focus therapeutic interventions on women who are more likely to deliver within the next 48 hours, whilst women in “false labor” can be offered supportive care and discharged. Therefore, a new diagnostic test that predicts PTB, using an easily accessible biological fluid (e.g. blood) and can be performed on all TPTL patients will be beneficial. This capability will allow a more rational approach to manage TPTL and provide considerable cost savings to the healthcare system. Recently, Chim and colleagues utilized gene expression microarray to identify placental genes associated with spontaneous PTB (sPTB) and subsequently screened for placental RNA transcripts and microRNAs in the maternal plasma in an attempt to discover novel biomarkers associated with sPTB [27].

Hence, this study utilized microarrays to characterize whole blood gene expression in women with TPTL. The specific hypotheses were: 1) women in TPTL who progress to true PTL and had a sPTB within 48 hours have a different gene expression profile compared with women who did not deliver within 48 hours, and 2) a genomic expression signature can predict sPTB within 48 hours in TPTL women. We obtained a nine gene signature coupled with peripheral clinical blood data to predict sPTB with 70.8% sensitivity and 75.5% specificity. Differentially expressed genes and their respective proteins may further elucidate the underlying mechanisms of sPTB and pave the way for the development of more precise and targeted therapies.

### Methods and Materials

#### Patient recruitment and ethics statement

The study was approved by the Ethics Committee, Department of Health, Government of Western Australia (EC05-34.3). Participants provided written consent; consent procedure was also

| Table 1. Clinical demographics of the 154 study participants. |
|---------------------------------------------------------------|
|                                                                 |
| | Spontaneous preterm birth within 48 hours | No spontaneous preterm birth within 48 hours | Mann-Whitney U Test (p-value) |
|-----------------------------------------------|-----------------------------------------------|-----------------------------|
| n                                 | Total | Preterm birth after 48 hours and within 7 days | Preterm birth at >7 days and <37 weeks | Term Delivery |
| Maternal Age (mean years ±SD) | 28.2±5.8 | 28.3±5.8 | 27.4±7.9 | 28.0±5.3 | 28.5±5.7 | 0.827 |
| Gestational Age at Presentation (mean weeks ±SD) | 31.7±3.2 | 30.9±2.8 | 28.8±3.0 | 31.4±1.4 | 31.2±2.9 | 0.044* |
| Gravidity (mean±SD) | 2±2 | 3±2 | 2±1 | 4±2 | 3±2 | 0.2 |
| Parity (mean±SD) | 1±1 | 2±2 | 1±1 | 2±1 | 2±2 | 0.2 |
| Cervical Dilatation at Presentation (mean cm±SD) | 2±1 | 1±1 | 2±1 | 1±1 | 1±1 | 0.2 |
| Gestational Age at Delivery (mean weeks ±SD) | 31.8±3.3 | 37.4±3.6 | 29.5±3.1 | 34.8±2.1 | 39.0±1.2 | <0.001* |
| Leukocyte Counts\* (mean 10⁹/L±SD) | 16.3±4.9 | 12.1±3.1 | 13.9±3.8 | 11.8±3.2 | 11.8±2.8 | <0.001* |
| Neutrophil Counts\* (mean 10⁹/L±SD) | 13.8±5.1 | 9.8±3.1 | 11.6±4 | 9.6±2.9 | 9.5±2.8 | <0.001* |
| Lymphocyte Counts\* (mean 10⁹/L±SD) | 6±28.8 | 1.6±0.7 | 1.6±0.5 | 1.6±0.8 | 1.6±0.8 | 0.204 |
| Monocyte Counts\* (mean 10⁹/L±SD) | 0.6±0.4 | 0.6±0.3 | 0.6±0.3 | 0.5±0.3 | 0.6±0.3 | 0.803 |
| Hemoglobin\* (mean grams/L±SD) | 122±15 | 119±10 | 123±12 | 123±13 | 118±10 | 0.275 |
| Previous Preterm Birth (n) | 7/48 (14.6%) | 25/106 (23.6%) | 5/12 (41.7%) | 7/15 (46.7%) | 13/79 (16.5%) |
| Smoker (n) | 14/48 (29.2%) | 29/106 (27.4%) | 4/12 (33.3%) | 3/15 (20.0%) | 22/79 (27.8%) |
| Fetal Fibronectin Performance | Total Tests (n) | 12/48 (25.0%) | 50/106 (47.2%) | 4/12 (33.3%) | 9/15 (60.0%) | 38/79 (48.1%) |
| Positive (n) | 10 | 17 | 3 | 6 | 8 |
| Negative (n) | 2 | 33 | 0 | 3 | 30 |

\*Peripheral blood data (total leukocytes, neutrophils, lymphocytes, monocytes counts and hemoglobin) were obtained from 125 women (<48 hours delivery n = 45, >48 hours delivery n = 80). *Significantly different between preterm delivery within 48 hours (n = 48) and no preterm delivery within 48 hours (n = 106).

doi:10.1371/journal.pone.0096901.t001
Gene Expression in Threatened Preterm Labor

Figure 1. The dot plots (mean and standard deviations) of gestational age at presentation of women who did or did not have a spontaneous preterm birth (sPTB) within 48 hours of hospital admission in the microarray (A) and qRT-PCR (B) study, respectively.

doi:10.1371/journal.pone.0096901.g001

approved by the Ethics Committee. The majority of participants were of Caucasian ethnicity. Using a two class comparison model (with restrictive inclusion and exclusion criteria), an alpha of 0.001, beta of 0.8, four technical replicates and estimating the gene expression variance in human biological samples to be 0.5, the minimum sample size to identify a two-fold change in gene expression is 26 patients (biological replicates) with 13 in each group. Given that the proportion of patients who will progress to preterm delivery is somewhat variable, 300 women admitted with TPTL were recruited from King Edward Memorial Hospital, Perth, WA, Australia. Inclusion criteria at recruitment were presentation between 24 to 36 weeks’ gestation, uterine contractions, with or without cervical changes, if dilated, cervix must be < 4 cm, intact fetal membranes and no evidence of clinical chorioamnionitis (febrile ≥37.5°C, uterine tenderness, mother systemically unwell, fetal tachycardia). Exclusion criteria were as follows: excessive antepartum hemorrhage, preterm prelabor rupture of membranes, clinical chorioamnionitis, fetal anomaly, preclampsia, intra-uterine growth restriction, diabetes mellitus or gestational diabetes or multi-fetal pregnancy.

IFN test (QuikCheck IFN, Hologic, Inc., Marlborough, MA) was performed where feasible (i.e. intact fetal membranes, no unprotected sexual intercourse in the preceding 48 hours, no prior vaginal examination and no bleeding) as part of the hospital’s protocol and for comparison with microarray data. High vaginal swabs and urine were collected from each participant for standard hospital bacteria vaginosis screening, microscopy, culture and sensitivities as part of their routine clinical care. Women who delivered preterm at our hospital had their placentae sent for microscopy, culture and formal histopathology. Clinical microbiology assessment of vagina, urine and placenta cultures and placenta histopathology were reported where available. The lack of placenta reports in women who did not deliver within 48 hours was either due to them subsequently delivering at another hospital or histology was not routinely performed on term placentas.

Participants were subsequently stratified into two groups: sPTB within 48 hours of hospital admission and no sPTB within 48 hours.

Blood sample collection, RNA extraction and quality check

Maternal blood samples were collected at point of hospital admission prior to any medical treatment. Five PAXgene blood collection tubes (PreAnalytics, Hombrechtikon, Switzerland) were collected from each participant, total RNA was isolated using PAXgene Blood RNA system kit (QIAGEN, Doncaster, Victoria, Australia). RNA quality check was done at The Centre for Applied Genomics (TCAG; The Hospital for Sick Children (SickKids), Toronto, ON, Canada) using an Agilent 2100 BioAnalyser with the RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA). The bioanalyzer provides a RNA integrity number (RIN) to gauge RNA integrity, compare samples and ensure the repeatability of experiments. RIN is calculated using an algorithm and the bioanalyzer’s electrophoretic trace where a RIN score of one represents strongly degraded RNA and a score of 10 represents intact RNA [28]. Adhering to TCAG’s protocol, microarrays were only performed on samples with RIN greater than six.

Microarray

Full microarray experiments were performed by TCAG. Total RNA samples were hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). The globin reduction protocol was incorporated into microarray processing [29]. Microarray data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE46510: (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46510).

Clinical data associated with the microarray data are presented in Table S1 in File S1.

Differential gene expression analysis

Affymetrix U133 Plus2 GeneChip CEL files were normalized using the GeneChip Robust Multiarray Average (GCRA) (Bioconductor, R). Custom (Gene)Chip Definition Files (CDFs) for Entrez Gene (version 17) were used to map Affymetrix GeneChip probes to transcripts/exons/genes for specific databases [30]. Differential gene expressions were analyzed using Limma (Bioconductor, R) [31]. To correct for multiple hypotheses testing, significant differentially expressed genes were identified based on a false discovery rate (FDR) threshold of <0.05 using the Benjamini and Hochberg approach. Fold changes were calculated using median values and expressed as logarithm base 2 (Log2).

Gene Ontology (GO) Slim annotations were obtained for significant genes (Limma FDR<0.05) [32,33]. Reactome Functional Interaction Cytoscape plug-in (version 4.0 beta) was used to visualize community networks and to determine if differently expressed genes (passing Limma FDR threshold of <0.05) may be enriched and form clusters of interconnected molecular events or
Reactions associated with sPTB within 48 hours [34,35]. Representative GO Slim terms were obtained for each cluster. Enrichment analyses using FuncAssociate 2.0 were performed separately on genes passing Limma FDR threshold of 0.1 that were either up or down regulated [36]; and pathway analyses were performed using DAVID Bioinformatics Resources 6.7 (BioCarta, KEGG and Panther) with genes passing Limma FDR threshold of 0.1 [37]. For both enrichment and pathway analyses, the total number of genes observed in the microarray (n = 19,008) was used as the background. A less stringent FDR of <0.1 allows more genes to be included in the analyses.

**Quantitative real-time PCR**

Quantitative real-time PCR (qRT-PCR) was performed to validate a subset of significant genes that displayed a \( \log_2 \) fold change of \( \pm 0.6 \) (i.e. \( \pm 50\% \) increase or \( \pm 34\% \) decrease in women who delivered within 48 hours) and a minimum average microarray intensity expression of \( >4 \) (CEL files arbitrary

| Table 2. Urine culture, vaginal microbiology and placental histopathology and microbiologic assessments of participants. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| **A. Urine and vaginal microbiology** | **Spontaneous preterm birth within 48 hours (n = 48)** | **No preterm birth within 48 hours (n = 106)** | **Fisher's test p-value** |
| Urine Culture (total n with reports) | 26 | 83 | 0.852 |
| No growth | 15 | 40 | |
| Mixed growth | 9 | 33 | |
| Pathogen isolated *Escherichia coli* positive | 1 | 2 | |
| *Bacillus cereus* positive | 1 | | |
| Group B streptococcus (GBS) and *Staphylococcus aureus* positive | 1 | | |
| Contamination reported | 1 | 6 | |
| No report available | 22 | 23 | |
| **Vaginal Culture (total n with reports)** | 29 | 77 | 0.189 |
| No growth | 3 | 3 | |
| Normal vaginal flora | 6 | 31 | |
| Ureaplasma spp. positive | 4 | 14 | |
| GBS positive | 3 | 7 | |
| *Candida* spp. positive | 3 | 9 | |
| Other pathogens isolated | | | |
| *Staphylococcus aureus* positive | | | |
| *Escherichia coli* or coliform bacteria positive | | | |
| Co-presence of \( \geq 2 \) microorganisms (*Candida* spp., *Ureaplasma* spp., GBS, *Mycoplasma* spp., *Neisseria* spp., *Gardnerella* spp., *Haemophilus* spp., unspecified coliform) | 8 | 12 | |
| No report available | 19 | 29 | |
| **B Placental histopathology and microbiologic assessments** | **Spontaneous preterm birth within 48 hours (n = 48)** | **No preterm birth within 48 hours (n = 106)** | **Fisher’s test p-value** |
| Histology consistent with immature placenta (total n) | 10 | 4 | 0.578 |
| No growth | 4 | 4 | |
| Mixed flora | 1 | | |
| GBS positive | 2 | | |
| Microbiology not performed | 3 | | |
| Chorioamnionitis (mild to severe) (total n) | 10 | 8 | |
| No growth | 3 | 4 | |
| Mixed flora | 2 | | |
| GBS or *Escherichia coli* or *Ureaplasma* spp. positive | 2 | 3 | |
| Microbiology not performed | 3 | 1 | |
| Decidual vasculopathy (total n) | 2 | 1 | |
| *Ureaplasma* spp. or *Mycoplasma hominis* or GBS positive | 2 | 1 | |
| Ischaemia (total n) | 1 | | |
| Microbiology not performed | 1 | | |
| No histopathology report (total n) | 26 | 92 | |
| doi:10.1371/journal.pone.0096901.t002 | | | |
expression values) [38,39]. Primers were designed using Primer BLAST. Primer specificities and efficiencies (65%–120%) were determined using pooled cDNA from 10 women (five term deliveries, five preterm deliveries) and five-point standard curves. Reverse transcription was performed to obtain 50 ng/μL cDNA using iScript (BIO-RAD, Hercules, CA): 25°C for 5 min, 85°C for 5 min. qRT-PCR was performed in triplicates using LuminosCt SYBR Green PCR ReadyMix (Sigma-Aldrich, St. Louis, MO): 90°C for 30 s, 56°C for 30 s, 60°C for 20 s (40 cycles) on the CFX384 Touch Real-Time PCR Detection System (BIO-RAD). Fold changes were calculated using median values.

### Statistical analysis

Demographics, peripheral clinical blood data and microbiology data comparison between women who did or did not have a sPTB within 48 hours were done using the Mann-Whitney U test and Fisher’s exact test; correlation was performed using Pearson’s r (Statistical Package for Social Sciences version 17.0, SPSS Inc, Chicago, IL). qRT-PCR data analyses were performed using binary logistic regression (LogXact 10, Cytel Inc, Cambridge, MA). The dot plots were produced using GraphPad Prism v5.02 (GraphPad Software, San Diego, CA).

### Random forest classifier

A random forest classifier model was constructed to differentiate between women who had a sPTB within 48 hours and those who did not. The dataset consists only of numeric values and missing values were imputed with the median across the samples. The model was built using the random forest implementation (randomForest version 4.6-7, R). Leave-one-out cross validation was performed to provide out-of-bag evaluation of the classifier’s performance. Receiver Operating Characteristics (ROC) curve was used to assess prediction performance.

### Results

Two hundred out of 300 samples were retrospectively selected based on delivery outcome and re-examined for eligibility adhering to our inclusion and exclusion criteria; 178 samples were confirmed for eligibility and sent to the microarray facility. Twenty four samples were unfavorable post RNA quality check or were confirmed for eligibility and sent to the microarray facility. Samples adhering to our inclusion and exclusion criteria; 178 samples were confirmed for eligibility and sent to the microarray facility. A random forest classifier model was constructed to differentiate between women who had a sPTB within 48 hours and those who did not. The dataset consists only of numeric values and missing values were imputed with the median across the samples. The model was built using the random forest implementation (randomForest version 4.6-7, R). Leave-one-out cross validation was performed to provide out-of-bag evaluation of the classifier’s performance. Receiver Operating Characteristics (ROC) curve was used to assess prediction performance.

### Table 3. Top twenty significantly expressed genes (FDR<0.05, Limma) ranked by fold change.

| Gene      | Fold change (Log2) | Fold change | Preterm birth within 48 hours Median expression (25th, 75th percentile) | No preterm birth within 48 hours Median expression (25th, 75th percentile) | FDR | Gene annotation |
|-----------|-------------------|-------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-----|-----------------|
| Up-regulated genes (n = 12) |
| ZDHHC19   | 1.202             | 2.30        | 4.66 (3.95, 5.51)                                                       | 3.47 (3.19, 4.21)                                                       | 0.00 | zinc finger, DHHC-type containing 19 |
| HPGD      | 1.049             | 2.07        | 5.80 (5.11, 7.60)                                                       | 5.08 (4.17, 6.95)                                                       | 0.047 | hydroxyprostaglandin dehydrogenase 15-(NAD) |
| GPR84     | 0.990             | 1.99        | 8.00 (6.77, 8.78)                                                       | 6.78 (6.40, 7.64)                                                       | 0.007 | G protein-coupled receptor 84 |
| OPLAH     | 0.934             | 1.91        | 6.62 (5.89, 7.90)                                                       | 5.82 (5.26, 6.69)                                                       | 0.003 | 5-oxoprolinase (ATP-hydrolysing) |
| TDR9      | 0.906             | 1.87        | 4.86 (3.68, 6.08)                                                       | 3.89 (3.24, 4.94)                                                       | 0.018 | tudor domain containing 9 |
| ATP9A     | 0.880             | 1.84        | 7.86 (6.73, 8.92)                                                       | 6.71 (6.15, 7.78)                                                       | 0.013 | ATPase, class II, type 9A |
| GALNT14   | 0.879             | 1.84        | 9.04 (8.46, 9.58)                                                       | 8.27 (7.86, 8.66)                                                       | 0.000 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetyl glycosaminyltransferase 14 |
| SLC26A8   | 0.802             | 1.74        | 7.53 (6.71, 8.08)                                                       | 6.76 (6.05, 7.48)                                                       | 0.015 | solute carrier family 26, member B |
| CDS5RAP2  | 0.768             | 1.70        | 8.73 (7.73, 10.10)                                                      | 8.12 (7.44, 8.80)                                                       | 0.017 | CD5 regulatory subunit associated protein 2 |
| ST3GAL4A51| 0.760             | 1.69        | 9.15 (8.41, 9.81)                                                       | 8.41 (7.71, 9.03)                                                       | 0.015 | ST3GAL4 antisense RNA 1 (head to head) |
| G0S2      | 0.758             | 1.69        | 7.56 (7.10, 8.05)                                                       | 6.83 (6.26, 7.53)                                                       | 0.006 | G0/G1switch 2 |
| SOCS3     | 0.757             | 1.69        | 8.45 (7.51, 9.13)                                                       | 7.77 (7.14, 8.22)                                                       | 0.003 | suppressor of cytokine signaling 3 |
| Down-regulated genes (n = 8) |
| METTL18   | -0.909            | 0.53        | 3.46 (2.73, 3.79)                                                       | 4.20 (3.52, 5.00)                                                       | 0.002 | methyltransferase like 18 |
| GOLGA8    | -0.874            | 0.55        | 8.48 (7.63, 9.36)                                                       | 9.32 (8.40, 10.26)                                                      | 0.037 | golgin A8 family, member A |
| ZNF302    | -0.802            | 0.57        | 3.20 (2.76, 3.53)                                                       | 3.51 (3.12, 4.37)                                                      | 0.007 | zinc finger protein 302 |
| TRMT13    | -0.797            | 0.58        | 4.10 (3.53, 5.12)                                                       | 5.19 (3.74, 6.15)                                                      | 0.047 | tRNA methyltransferase 13 homolog (S. cerevisiae) |
| CETN3     | -0.773            | 0.59        | 4.20 (3.01, 4.36)                                                       | 4.41 (3.98, 5.70)                                                      | 0.032 | centrin, EF-hand protein, 3 |
| ZFAND1    | -0.771            | 0.59        | 5.35 (4.68, 6.31)                                                       | 6.18 (5.12, 6.99)                                                      | 0.040 | zinc finger, AN1-type domain 1 |
| STAP1     | -0.764            | 0.59        | 4.10 (3.52, 4.52)                                                       | 4.78 (4.09, 5.50)                                                      | 0.007 | signal transducing adaptor family member 1 |
| MS4A1     | -0.758            | 0.59        | 6.93 (6.09, 7.55)                                                       | 7.76 (6.97, 8.69)                                                      | 0.028 | membrane-spanning 4-domains, subfamily A, member 1 |

DOI: 10.1371/journal.pone.0096901.t003
Figure 2. GO Slim terms of (A) cellular components, (B) molecular functions and (C) biological process that are representative of the 469 significantly expressed genes.

doi:10.1371/journal.pone.0096901.g002
a sPTB within 48 hours. Figure 1 displays the gestational age at presentation of women in the microarray and qRT-PCR studies, respectively. Peripheral blood clinical laboratory results were obtained from 125 women. Total leucocyte and neutrophil counts were 34.7% and 40.8% higher in women who had sPTB within 48 hours of hospital admission ($p<0.001$). There were no differences in urine culture, vaginal microbiology as well as placental histopathology and microbiology assessment between the two groups ($p>0.05$; Table 2). No woman had bacteria vaginosis.

**Identification of differentially expressed genes using microarray**

As gestational age at presentation was significantly different between women who did or did not have a sPTB within 48 hours, this suggested that gene expression in whole blood may be gestational age dependent. We thus analyzed the microarray data by pairing matched gestational age samples using a modified *Lima* design matrix (moderated paired *t*-test). Samples were rounded down to the nearest gestational week and then grouped according to their gestational age at presentation. Data analysis using *Lima* obtained 469 significantly differentially expressed genes (256 up-regulated genes, 213 down-regulated genes, FDR, $0.05$; Table S2 in File S1). Table 3 displays the top 20 up and down regulated genes (ranked by Log$_2$ fold change). Of the 469 significant genes, 176 genes were confidently mapped to relevant GO Slim terms, 254 genes were reported as ambiguous and 39 genes were not annotated [32] (Figure 2).

**Enrichment analyses**

From the Reactome network constructed around the 469 differentially expressed genes (*Lima* FDR $<0.05$), eight major clusters with minimum five genes were discovered. These clusters generally represent metabolic process, response to stress, immune system process and signal transduction (Figure 3). A total of 1333 genes (*Lima* FDR $<0.1$) were subjected to functional enrichment analysis. Enrichment analyses found 14 functions (odds ratio $>2$) significantly enriched in 570 up-regulated genes and 17 functions (odds ratio $>2$) significantly enriched in 763 down-regulated genes (Table 4). No significant pathway analysis was obtained using DAVID.

**Validation of microarray using qRT-PCR analysis**

Twenty eight differentially expressed genes ($\pm 0.6$ Log$_2$ fold change and $\geq 4$ microarray intensity expression) were chosen for microarray data validation using qRT-PCR. A total of ninety six samples (a subset of the 154 women) were selected for qRT-PCR validation: 41 samples from women who had sPTB within 48 hours were used and 55 samples were randomly chosen from the 106 women who did not deliver within 48 hours. After adjusting for gestational age at presentation, qRT-PCR confirmed the differential expression of 20 genes ($p<0.05$) and the direction of change in all 28 genes were 100% consistent with the microarray analysis (Table S3 in File S1). There was a significant correlation between microarray and qRT-PCR data (Pearson’s $r = 0.956$, $p<0.001$).

**Generation of models to predict sPTB within 48 hours**

Optimal random forest classifier model performances was achieved using the top nine differentially expressed genes...
Table 4. Functional enrichment analysis of a total of 1333 genes (FDR<0.1, Limma) resulted in 31 enriched GO terms with odds ratio of >2 (adjusted p<0.05).

| Gene Ontology ID | Gene Ontology annotation                           | Odds ratio | Adjusted p value | Number of enriched genes/Total number of genes in annotation set (n) |
|------------------|-----------------------------------------------------|------------|-----------------|---------------------------------------------------------------|
| GO:0046339       | diacylglycerol metabolic process                     | 41.13      | 0.044           | 4/7                                                           |
| GO:0050727       | regulation of inflammatory response                  | 4.21       | 0.044           | 14/125                                                        |
| GO:0052548       | regulation of endopeptidase activity                | 3.70       | 0.003           | 21/210                                                        |
| GO:0052547       | regulation of peptidase activity                    | 3.61       | 0.003           | 21/215                                                        |
| GO:0006954       | inflammatory response                               | 3.18       | 0.012           | 23/264                                                        |
| GO:0031347       | regulation of defense response                       | 2.86       | 0.007           | 28/354                                                        |
| GO:0009611       | response to wounding                                | 2.78       | <0.001          | 56/744                                                        |
| GO:0050878       | regulation of body fluid levels                     | 2.66       | 0.002           | 36/490                                                        |
| GO:0007596       | blood coagulation                                   | 2.64       | 0.005           | 33/451                                                        |
| GO:0050817       | coagulation                                         | 2.62       | 0.005           | 33/453                                                        |
| GO:0007599       | hemostasis                                          | 2.61       | 0.007           | 33/455                                                        |
| GO:0001775       | cell activation                                     | 2.61       | 0.002           | 37/512                                                        |
| GO:0080134       | regulation of response to stress                    | 2.46       | 0.001           | 43/631                                                        |
| GO:0016192       | vesicle-mediated transport                          | 2.33       | 0.005           | 42/646                                                        |
| GO:0006405       | RNA export from nucleus                             | 5.78       | 0.011           | 13/68                                                         |
| GO:0015931       | nucleobase-containing compound transport            | 5.08       | 0.004           | 16/93                                                         |
| GO:0050657       | nucleic acid transport                              | 5.05       | 0.028           | 13/76                                                         |
| GO:0050658       | RNA transport                                       | 5.05       | 0.028           | 13/76                                                         |
| GO:0051236       | establishment of RNA localization                   | 5.05       | 0.028           | 13/76                                                         |
| GO:0006403       | RNA localization                                    | 4.75       | 0.05            | 13/80                                                         |
| GO:000956        | nuclear-transcribed mRNA catabolic process          | 4.40       | 0.005           | 18/118                                                        |
| GO:0006402       | mRNA catabolic process                              | 4.00       | 0.012           | 18/128                                                        |
| GO:0006401       | RNA catabolic process                               | 3.67       | 0.011           | 20/153                                                        |
| GO:0006396       | RNA catabolic process                               | 2.81       | <0.001          | 43/419                                                        |
| GO:0006412       | translation                                         | 2.63       | 0.048           | 28/287                                                        |
| GO:0016071       | mRNA metabolic process                              | 2.60       | 0.002           | 40/417                                                        |
| GO:0022402       | cell cycle process                                  | 2.13       | 0.001           | 65/819                                                        |
| GO:0005634       | nucleus                                             | 2.08       | <0.001          | 244/355                                                       |
| GO:0000278       | mitotic cell cycle                                  | 2.07       | 0.028           | 49/628                                                        |
| GO:0007049       | cell cycle                                          | 2.05       | 0.001           | 76/999                                                        |
| GO:0044428       | nuclear part                                        | 2.01       | <0.001          | 130/1798                                                      |

doi:10.1371/journal.pone.0096901.t004

Comparison of gene signatures and fFN
To obtain an unbiased performance comparison between the microarray genomic signature and fFN, separate classifier models were constructed on the subset of patients who had corresponding fFN test results (n = 62). Table 5 also displays the comparison of the predictive efficacies of the random forest classifier models (using top nine genes, with and without clinical blood data, and with and without fFN test results included in the model) and the stand-alone fFN test to predict sPTB within 48 hours in 62 women (Figure 4B).

Discussion
This study has utilized microarrays to provide novel genomic insights of sPTB and our Limma analysis revealed 469 differentially expressed genes associated with sPTB within 48 hours in women with TPTL. PTB is a heterogeneous condition with varying etiologies. We accounted for known causes of PTB with our

Table 4.
exclusion criteria and attempted to discover a blood-based gene signature to predict imminent idiopathic sPTB. Labor is an inflammatory process with elevated levels of maternal circulating leukocytes [41,42] and increased leukocyte infiltration into the myometrium, decidua, and cervix before and during labor [43–45]. Thus, it was unsurprising to observe elevated whole blood mRNA expression of cytokines (IL-1β, OSM), cytokine/chemokine receptors (IL-4R, IL10RB, TNFRSF10D, LTBR, CCR1, CXCR1), Table 5.

| Gene Expression in Threatened Preterm Labor |
|----------------------------------------------|
| Table 5. Predicting spontaneous preterm birth within 48 hours in 154 women using the top 9 genes (with and without peripheral clinical blood data) and comparing the predictive efficacies of fetal fibronectin and the random forest classifier models (top 9 genes, with or without peripheral clinical blood data and fFN) to predict spontaneous preterm birth within 48 hours in 62 women. |
| | Top 9 Genes | Fetal Fibronectin only | Top 9 Genes |
| | Women, n | 154 | 154 | 62 | 62 | 62 | 62 |
| Clinical Blood Data (included in model) | Yes | No | - | Yes | No | Yes | No |
| Fetal Fibronectin (included in model) | - | - | - | - | - | Yes | Yes |
| ROC-AUC | 0.798 | 0.733 | - | 0.926 | 0.794 | 0.888 | 0.794 |
| p-value | <0.001 | <0.001 | - | 0.002 | <0.001 | <0.001 | 0.002 |
| Classifier Score Cut Off | 0.400 | 0.530 | - | 0.450 | 0.540 | 0.500 | 0.590 |
| Sensitivity (%) | 70.8 | 54.2 | 83.3 | 91.7 | 58.3 | 83.3 | 58.3 |
| Specificity (%) | 75.5 | 83.0 | 66.0 | 88.0 | 80.0 | 94.0 | 84.0 |
| Positive Predictive Value (%) | 56.7 | 59.1 | 37.0 | 64.7 | 41.2 | 76.9 | 46.7 |
| Negative Predictive Value (%) | 85.1 | 80.0 | 94.3 | 97.8 | 88.9 | 95.9 | 89.4 |
| False Positive (%) | 24.5 | 17.0 | 34.0 | 12.0 | 20.0 | 6.0 | 16.0 |
| False Negative (%) | 29.2 | 45.8 | 16.7 | 8.3 | 41.7 | 16.7 | 41.7 |
| doi:10.1371/journal.pone.0096901.t005 |

Figure 4. Receiver operator characteristics curves displaying the performances of the random forest classifier models. (A) Models using the top nine genes, with and without peripheral clinical blood data in 154 women. (B) Models developed using the top nine genes, fetal fibronectin (fFN) and clinical blood data in 62 women. The lines for nine genes only and nine genes with fFN are superimposed. doi:10.1371/journal.pone.0096901.g004
genes involved in cytokine signaling pathways (JAK3, TNIP2, SOCS3) and related transcriptional factors (NFκB1, JUNB) in our Limma differential analysis as well as inflammation-related clusters (Reactome) and enriched GO terms (FuncAssociate) in women who had sPTB within 48 hours. This suggests that a repertoire of inflammatory markers in the blood are differentially expressed 48 hours prior to labor and associated with impending delivery.

There is a wealth of information linking infection and PTB (reviewed in [4,46,47]). Despite our attempt to study idiopathic sPTB, these participants may have undiagnosed sub-clinical infection. Thus, the differential expression of infection- or inflammation-related genes in our study could be attributed to a combination of infection and labor. For example, inflammatory-related genes and their respective proteins such as NFKB1 [48], CCR1 [49], SOCS3, JAK3 [50], JUNB [51], RHOG [52], TIMP1 [53], IL1beta [54–57], ITGAM [58], CD44 [59,60], TLR5 [61–63] and CXCR1 [64,65] from our Reactome analysis are known to be up-regulated in reproductive tissues and other biologic fluids during term labor or PTL with or without infection. CD63 was increased in our study but fetal blood CD63 was not associated with sPTB [66]. Whole blood is widely studied [67,68] because it serves as reservoir that collects information from various physiologic processes such as immune response and cell-cell communication. It can be assumed that differentially expressed whole blood mRNAs are in part, contributed by activated maternal peripheral leukocytes with impending labor [69,70]. We observed an increase in peripheral blood leukocyte counts in women who delivered within 48 hours and this increase appears to be mainly contributed by neutrophils. This phenomenon agrees with the study by Campbell et al where women with TPTL without infection had increased leukocyte counts [71] and supports previous studies which reported increased circulating maternal leukocytes before and during labor [41,42,72–75]. Thus, our study has identified novel genes, most likely originating from leukocytes, which may serve as therapeutic targets for sPTB prevention.

We decided to focus our discussion on the top three differentially expressed genes, ZDHHC19, HPGD and GPR84. ZDHHC19 (2.3-fold increase) belongs to a family of palmitoyltransferases/acyltransferases that catalyzes post-translational attachment of palmitic acid groups onto cysteine residues via thioester linkage (i.e. palmitoylation) on newly synthesized protein substrates, thereby enhancing the association of these palmitoylated proteins with lipid bilayers of the plasma membrane and transport vesicles [76,77]. The up-regulation of ZDHHC19 in women who delivered within 48 hours could be linked to protein palmitoylation and the regulation of signaling pathways involving R-Ras and PDE10A2 in peripheral leukocytes.
HPGD demonstrated a 2.1-fold increase in women who had a sPTB within 48 hours. HPGD catalyzes prostaglandin into inactive keto-metabolites. HPGD is expressed in reproductive tissues, especially in the myometrium [80], chorion [81] and cervix [92]. HPGD is significantly decreased during term and PTL [80–85], thus promoting the effect of prostaglandin during labor [84,85]. The increase in whole blood HPGD mRNA may be a homeostatic response to the elevated concentration of prostaglandin-associated with impending labor onset [86,87].

GPR84 (2.0-fold increase) is a G protein-coupled receptor highly expressed in immune cells such as microglia, monocytes and neutrophils [88–91]. It is activated by medium-chain (C6-C14) free fatty acids (FFAs) such as capric, undecanoic and lauric acids [89] but not medium-chain triglycerides [92]. Hyper production of IL-4 occurs in GPR84−/− activated T-cells displaying T helper 2 phenotype [90]. Lipopolysaccharide (LPS) increases GPR84 expression in monocytes and microglia [88,89]. In addition, medium-chain FFAs can enhance LPS-stimulated secretion of the pro-inflammatory cytokine, IL-12 p40, via GPR84 in monocytes [89] while TNF and IL-1 can also increase GPR84 mRNA expression in microglia [88]. The increase in GPR84 mRNA in our study could be contributed by leukocytes which are stimulated by IL-1 and TNF in the serum [93,94], or suggests the potential novel involvement of medium-chain FFAs in signaling pathways and immunologic regulation prior to and during labor.

From our bioinformatics modeling of all 154 women, a set of nine genes coupled with clinical blood data could classify women who would or would not have a sPTB within 48 hours of hospital admission with 70.8% sensitivity and 75.5% specificity. The next step was to benchmark the performance of the stand-alone fFN test and our nine gene signature. fFN was only performed on 62 eligible women. When we modeled data from these 62 women, the nine genes coupled with clinical blood data was the best performing model with the highest area under ROC curve. It had improved sensitivity (91.7% vs 83.3%) and specificity (88.0% vs 66.0%) compared with the stand-alone fFN test. The effect of fFN was generally minimal (identical or lower area under the ROC curves) when fFN was included as a feature in the classifier models. The minimal contribution of fFN in the models may be because whole blood mRNA and fFN represent two fundamentally different elements of the parturition process - fFN indicates a disruption of the maternal-fetal interface and activated leukocytes contribute to the process of labor. However, it was also interesting to note that the addition of fFN into the model shifted the performance of the original model (nine genes and clinical blood data) from being a highly sensitive test to a more specific test (nine genes, clinical blood data and fFN) to predict sPTB. This influence may be attributed to the high specificity (NPV) of the fFN test [13].

The heterogeneity of sPTB and the inability to identify sub clinical patients may explain the small fold changes observed in this study and why no significant pathway analysis was obtained. This is a common challenge in PTL discovery or diagnostic studies. Moreover, our findings are limited to our institution with a homogenous population and therefore, the generalizability of our gene signatures is limited. Nevertheless, this gene expression study provides a broad overview of the mechanisms of sPTB and generates future hypotheses to investigate molecular interactions of various cell types (e.g. leukocytes) and reproductive tissues (e.g. placenta and myometrium) associated with sPTB. The predictive efficacy of our nine gene signature coupled with clinical blood data outperformed the fFN test and highlights the advantage of utilizing a blood-based diagnostic test for sPTB where all women could be tested. This study may lead the way for a blood-based systems biology approach to sPTB in the future.

Supporting Information

File S1 Contains the following files: Table S1. Clinical data of 154 women (GEO microarray submission). Table S2. The list of 469 significant differentially expressed genes obtained using Llimma ranked by magnitude of fold change. Table S3. Microarray and quantitative real-time-PCR of the selected 28 genes. (DOCX)

Acknowledgments

The authors thank the medical and midwifery staff at the King Edward Memorial Hospital for their assistance in sample collection; Karen Roberts and Peiling Tan (UWA) for sample processing; Dr Chao Lu and Xiaolin Wang (TCAG) for their service with the Agilent BioAnalyzer and Affymetrix microarrays; Alexandra Warwick and Jingxiong Xu (LTRI) for technical assistance and statistical advice; and Drs Oksana Shynlova and Caroline Dunk (LTRI) for reviewing the manuscript.

Author Contributions

Conceived and designed the experiments: YJH SJL. Performed the experiments: YJH JEP. Analyzed the data: YJH HNC. Contributed reagents/materials/analysis tools: CEP SJL HNC. Wrote the paper: YJH HNC SJL. Clinical input: CEP. The authors thank the medical and midwifery staff at the King Edward Memorial Hospital for their assistance in sample collection; Karen Roberts and Peiling Tan (UWA) for sample processing; Dr Chao Lu and Xiaolin Wang (TCAG) for their service with the Agilent BioAnalyzer and Affymetrix microarrays; Alexandra Warwick and Jingxiong Xu (LTRI) for technical assistance and statistical advice; and Drs Oksana Shynlova and Caroline Dunk (LTRI) for reviewing the manuscript.

References

1. Krupa FG, Falhin D, Cecatti JG, Surita FG, Souza JP (2006) Predictors of preterm birth. Int J Gynaecol Obstet 94: 5–11.
2. Ward RM, Beachy JC (2005) Neonatal complications following preterm birth. BJOG 110 Suppl 20: 8–16.
3. Petrou S (2005) The economic consequences of preterm birth during the first 10 years of life. BJOG 112: 10–15.
4. Institute of Medicine (2007) Preterm Birth: Causes, Consequences, and Prevention; Behrman RE, Butler AS, editors. Washington DC: National Academies Press.
5. Maningham LJ, Petrou S, Doyle LW, Draper ES, Marlow N (2009) The cost of preterm birth throughout childhood in England and Wales. Pediatrics 123: e312–e327.
6. Canadian Institute for Health Information (2009) Too early, too small: a profile of small babies across Canada. Ottawa, ON: CIHI.
7. Lim G, Tracey J, Boon M, Karmakar S, Wang J, et al. (2009) CIIH survey: Hospital costs for preterm and small-for-gestational age babies in Canada. Health Q 12: 19–24.
8. DeFranco EA, Lewis DF, Odibo AO (2013) Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol 208: 233.e231–236.
9. Katz M, Goodyear K, Creasy RK (1990) Early signs and symptoms of preterm labor. Am J Obstet Gynecol 162: 1150–1153.
10. Copper RL, Goldenberg RL, Davis RO, Cutrer GR, DuBard MB, et al. (1990) Warning symptoms, uterine contractions, and cervical examination findings in women at risk of preterm delivery. Am J Obstet Gynecol 162: 748–754.
11. Iams JD, Creasy RK (2004) Preterm labor and delivery. In: Creasy RK, Resnik R, Iams JD, editors. Maternal-Fetal Medicine: Principles and Practice. 5th ed. Philadelphia: Saunders.
12. Lyndon A (2006) Preterm labor and birth: where are we now? J Perinat Neonatal Nurs 20: 82–84.
13. Goldenberg RL (2002) The management of preterm labor. Obstet Gynecol 100: 1020–1037.
14. McPheeters ML, Miller WC, Hartmann KE, Savitz DA, Kaufman JS, et al. (2002) The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 192: 1325–1329; discussion 1329–1330.
15. Honest H, Bachamann LM, Gupta JK, Kleijnen J, Khan KS (2002) Accuracy of warning symptoms, uterine contractions, and cervical examination findings in women at risk of preterm delivery. Am J Obstet Gynecol.
16. Lucovnik M, Chambliss LI, Garfield RE (2013) Costs of Unnecessary Admissions and Treatments for “Threatened Preterm Labor”. Am J Obstet Gynecol.
17. Nicholson NK, Frick KD, Pose NR (2000) Economic burden of hospitalizations for preterm labor in the United States. Obstet Gynecol 96: 85–101.
18. Crowley P (2003) Antenatal corticosteroids—current thinking. BJOG 110 Suppl 20: 77–78.
Gene Expression in Threatened Preterm Labor

19. Crudo A, Petropoulos S, Miosaida VG, Ishai M, Kostaki A, et al. (2012) Prenatal synthetic glucocorticoid treatment changes DNA methylation states in male organ systems: multigenerational effects. Endocrinology 153: 3269–3283.

20. Murphy KE, Hannah ME, Willan AR, Olohsen A, Kelly EN, et al. (2011) Maternal side-effects after multiple courses of antenatal corticosteroids (MACS): the three-month follow-up of women in the randomized controlled trial of MACS for preterm birth study. J Obstet Gynaecol Can 33: 909–921.

21. Murphy KE, Willan AR, Hannah ME, Olohsen A, Kelly EN, et al. (2012) Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol 119: 917–923.

22. Azezale EV, Murphy KE, Hannah ME, Willan AR, Mathews SG, et al. (2010) Multiple courses of antenatal corticosteroids for preterm birth study: 2-year outcomes. Pediatr Res 67: e149–e155.

23. Goffinet F (2005) Primary predictors of preterm labour. BJOG 112: 38–47.

24. Larra JM, Iams JD (2013) Is sonographic assessment of the cervix necessary and helpful? Clin Obstet Gynecol 56: 324–335.

25. Lockwood CJ, Senyi AE, Dicheir MR, Casal D, Shah KD, et al. (1991) Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 326: 669–674.

26. Leitch H, Egarter C, Kaider A, Hehlhagwandtner M, Bergthammer P, et al. (1999) Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-analysis. Am J Obstet Gynecol 180: 1119–1176.

27. Chinn SS, Lee WS, Ting YH, Chan OK, Lee SW, et al. (2012) Systematic identification of spontaneous preterm birth-associated RNA transcripts in maternal plasma. PLoS One 7:e35282.

28. Severud A, Majors R, Stocker S, Salovsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.

29. Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, et al. (2009) Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics 10: 2.

30. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.

31. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: DS26-DS34.

32. Newman ME (2006) Modularity and community structure in networks. Proc Natl Acad Sci U S A 103: 8577–8582.

33. Berri GF, Beaver JE, Cenik C, Tasan M, Roth FP (2009) Next generation software for functional trend analysis. Bioinformatics 25: 3043–3049.

34. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 41–50.

35. Newman ME (2006) Modularity and community structure in networks. Proc Natl Acad Sci U S A 103: 8577–8582.

36. Davis JS, Ryan JC, Van Dobhal FM (2006) Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online 8: 175–193.

37. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, et al. (2005) Gene expression in Threatened Preterm Labor

38. Efrati P, Presentey B, Margalith M, Rozenszajn L (1964) Leukocytes of normal membranes, decidua, cervix and myometrium before and during labour at term. J Leukoc Biol 72: 874–884.

39. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, et al. (2005) Gene expression in Threatened Preterm Labor

40. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: research0034.0034.0011.

41. Efрат P, Presentey B, Margalith M, Rosseznij L (1964) Leukocytes of normal membranes, decidua, cervix and myometrium before and during labour at term. J Leukoc Biol 72: 874–884.

42. Lim R, Barker G, Lappas M (2013) SIRT6 is decreased with preterm labor and regulates key terminal effecter pathways of human labor in fetal membranes. Biomed Rep 8: 17.

43. Kaukola T, Ojanenm L, Tuimala J, Herva R, Saarela T, et al. (2011) Cord blood chemokines differ between spontaneous and elective preterm births in singleton pregnancies. Cytokine 54: 83–91.

44. Goldenberg RL, Culhane JD, Iams JD, Romero R (2008) Epidemiology and outcomes. Pediatr Res 67: 91–98.

45. Nakai T, Ishihara I, Takahashi R, Yamaoka H, Yoshimura A (2011) Suppression of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of Toll-like receptor 4 activation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 31: 980–985.

46. Mitchell JA, Shynoiva O, Langille BL, Lye SJ (2004) Mechanical stretch and progestrone differentially regulate activator protein-1 transcription factors in primary rat myometrial smooth muscle cells. Am J Phys Endocrinol Metab 287: E439–445.

47. Larrey J, Lepage Bernal B (2009) RH0 protein regulation of contraction in the human uterus. Reproduction 138: 407–424.

48. Lim R, Barker G, Lappas M (2013) SIRT6 is decreased with preterm labor and regulates key terminal effecter pathways of human labor in fetal membranes. Biomed Rep 8: 17.
75. Shynlova O, Perrnell C, Whittle W, Lye S (2009) Increased maternal peripheral white blood cell count is a marker of active human labor. Reprod Sci 16: 223A.
76. Greaves J, Chamberlain LH (2011) DHHC palmitoyl transferases: substrate interactions and (patho)physiology. Trends Biochem Sci 36: 245–253.
77. Baumgart F, Corral-Escariz M, Perez-Gil J, Rodriguez-Crespo J (2010) Palmitoylation of R-Ras by human DHHC19, a palmitoyl transferase with a CaaX box. Biochim Biophys Acta 1798: 592–604.
78. Korycka J, Lach A, Heger E, Boguslawska DM, Wolny M, et al. (2012) Human DHHC proteins: a spotlight on the hidden player of palmitoylation. Eur J Cell Biol 91: 107–117.
79. Charych EI, Jiang LX, Lo F, Sullivan K, Brandon NJ (2010) Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. J Neurosci 30: 9027–9037.
80. Giannoulias D, Patel FA, Holloway AC, Lye SJ, Tai HH, et al. (2002) Differential changes in 15-hydroxyprostaglandin dehydrogenase and prostaglandin H synthase (types I and II) in human pregnant myometrium. J Clin Endocrinol Metab 87: 1345–1352.
81. Sangha RK, Walton JC, Enoor CM, Tai HH, Challa JR (1994) Immunobistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor. J Clin Endocrinol Metab 78: 902–909.
82. Toribio SA, Patel FA, Bystrom R, Giannoulias D, Malstrom A, et al. (2004) 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase 2 messenger ribonucleic acid expression and immunobistochemical localization in human cervical tissue during term and preterm labor. J Clin Endocrinol Metab 89: 2909–2915.
83. van Meir CA, Matthews SG, Krise MJ, Ramirez MM, Bocking A, et al. (1997) 15-hydroxyprostaglandin dehydrogenase: implications in preterm labor with and without ascending infection. J Clin Endocrinol Metab 82: 969–975.
84. Johnson RF, Mitchell CM, Clifton V, Zakar T (2004) Regulation of 15-hydroxyprostaglandin dehydrogenase (PGDH) gene activity, messenger ribonucleic acid processing, and protein abundance in the human chorion in late gestation and labor. J Clin Endocrinol Metab 89: 5639–5648.
85. Welsh T, Paul J, Palliser HK, Tabatabaee H, Hirst J, et al. (2012) 15-Hydroxyprostaglandin dehydrogenase expression and localization in guinea pig gestational tissues during late pregnancy and parturition. Reprod Sci 19: 1099–1109.
86. Karim SM (1968) Appearance of prostaglandin F2-alpha in human blood during labour. Br Med J 1: 616–621.
87. Brunner HC (1972) Serum PGE2 alpha levels during late pregnancy, labour and the puerperium. Prostaglandins 2: 185–194.
88. Bouchard C, Page J, Bedard A, Tremblay P, Vallieres L (2007) G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia 55: 790–800.
89. Wang J, Wu X, Simonavicius N, Tian H, Ling L (2006) Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 281: 34457–34464.
90. Venkataraman C, Kuo F (2005) The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 cross-linking. Immunol Lett 101: 144–153.
91. Yousefi S, Cooper PR, Potter SL, Muenn C, Jarai G (2003) Cloning and expression analysis of a novel G-protein-coupled receptor selectively expressed on granulocytes. J Leukoc Biol 69: 1045–1052.
92. Verdelien MW, van Esterik JC, Roelofs HM, van Enst-de Vries SE, Willems PH, et al. (2009) Parenteral medium-chain triglyceride-induced neutrophil activation is not mediated by a Pertussis Toxin sensitive receptor. Clin Nutr 28: 59–64.
93. Urnal ER, Cierny JT, Roedner C, Newman R, Goetzl E (2011) Maternal inflammation in spontaneous term labor. Am J Obstet Gynecol 204: 223.e221–225.
94. Torbey A, Czajka R, Kordek A, Rzezka R, Kwiecikowski S, et al. (2007) Maternal serum proinflammatory cytokines in preterm labor with intact membranes: neonatal outcome and histological associations. Eur J Immunol 37: 102–107.